Tag Archives: Cory Kasimov

J.P. Morgan Maintains Their Buy Rating on Incyte Corp (INCY)

In a report issued on May 12, Cory Kasimov from J.P. Morgan maintained a Buy rating on Incyte Corp (INCY – Research Report), with a price target of $90. The company’s shares closed yesterday at $76.11. According to TipRanks.com, Kasimov

J.P. Morgan Sticks to Their Hold Rating for Acorda Therapeutics (ACOR)

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Acorda Therapeutics (ACOR – Research Report) on May 2 and set a price target of $18. The company’s shares closed yesterday at $12.10, close to its 52-week low of $9.58.

Gilead Sciences (GILD) Gets a Buy Rating from J.P. Morgan

J.P. Morgan analyst Cory Kasimov assigned a Buy rating to Gilead Sciences (GILD – Research Report) on May 2 and set a price target of $87. The company’s shares closed yesterday at $67.69. According to TipRanks.com, Kasimov is a 3-star

Analysts Have Conflicting Sentiments on These Healthcare Companies: ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) and Dexcom (NASDAQ: DXCM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ACADIA Pharmaceuticals Inc (ACAD – Research Report) and Dexcom (DXCM – Research Report). ACADIA Pharmaceuticals Inc (ACAD) J.P. Morgan analyst Cory Kasimov maintained

Vertex Pharmaceuticals (VRTX) Receives a Buy from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $209. The company’s shares closed yesterday at $168.98. According to TipRanks.com, Kasimov is a 2-star analyst with

Incyte Corp (INCY) Gets a Buy Rating from J.P. Morgan

In a report released today, Cory Kasimov from J.P. Morgan maintained a Buy rating on Incyte Corp (INCY – Research Report). The company’s shares opened today at $74.61. According to TipRanks.com, Kasimov is a 2-star analyst with an average return